Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för CPMG Inc. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att CPMG Inc har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:PRCT / PROCEPT BioRobotics Corporation | 10% Owner | 2 823 681 |
US:RETA / Reata Pharmaceuticals Inc - Class A | Director, 10% Owner | 0 |
US:APEN / Apollo Endosurgery Inc | 10% Owner | 0 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av CPMG Inc. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp PRCT / PROCEPT BioRobotics Corporation - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i PRCT / PROCEPT BioRobotics Corporation. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-09-17 | PRCT | CPMG Inc | 440 000 | 25,0000 | 440 000 | 25,0000 | 11 000 000 | 357 | 50.6500 | 11 286 000 | 102,60 |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i PRCT / PROCEPT BioRobotics Corporation. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av CPMG Inc som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-05-07 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
J - Other | −1 785 127 | 2 823 681 | −38,73 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −134 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −11 076 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −160 265 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −334 740 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −37 909 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −109 415 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −431 155 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −748 253 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −442 560 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −34 897 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −44 200 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −5 464 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −137 962 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −282 246 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −116 512 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −113 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −31 467 | 0 | −100,00 | ||||
2023-04-04 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
D - Sale to Issuer | −400 675 | 0 | −100,00 | ||||
2023-04-04 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
D - Sale to Issuer | −63 671 | 0 | −100,00 | ||||
2023-04-04 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
D - Sale to Issuer | −45 594 | 0 | −100,00 | ||||
2023-04-04 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
D - Sale to Issuer | −3 687 781 | 0 | −100,00 | ||||
2023-04-04 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
D - Sale to Issuer | −1 310 701 | 0 | −100,00 | ||||
2023-04-04 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
D - Sale to Issuer | −675 181 | 0 | −100,00 | ||||
2022-12-30 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
C - Conversion | 1 465 770 | 3 687 781 | 65,97 | 3,25 | 4 763 752 | 11 985 288 | |
2022-12-30 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
C - Conversion | 586 308 | 1 310 701 | 80,94 | 3,25 | 1 905 501 | 4 259 778 | |
2022-12-30 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
C - Conversion | 146 577 | 675 181 | 27,73 | 3,25 | 476 375 | 2 194 338 | |
2022-12-07 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
J - Other | −1 726 534 | 5 029 869 | −25,55 | ||||
2022-11-16 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
J - Other | −1 729 482 | 6 993 137 | −19,83 | ||||
2022-09-13 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
J - Other | −986 640 | 8 955 675 | −9,92 | ||||
2022-09-08 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
J - Other | −743 021 | 10 075 491 | −6,87 | ||||
2022-03-21 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
J - Other | −304 268 | 10 918 394 | −2,71 | ||||
2021-10-19 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
P - Purchase | 387 097 | 2 151 209 | 21,94 | 7,75 | 3 000 002 | 16 671 870 | |
2021-10-19 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
P - Purchase | 258 064 | 696 071 | 58,92 | 7,75 | 1 999 996 | 5 394 550 | |
2021-10-19 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
P - Purchase | 38 710 | 521 522 | 8,02 | 7,75 | 300 002 | 4 041 796 | |
2021-09-21 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Series G Convertible Preferred Stock |
C - Conversion | −272 205 | 0 | −100,00 | ||||
2021-09-21 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Series F Convertible Preferred Stock |
C - Conversion | −2 060 802 | 0 | −100,00 | ||||
2021-09-21 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Series E Convertible Preferred Stock |
C - Conversion | −3 038 934 | 0 | −100,00 | ||||
2021-09-21 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Series D Convertible Preferred Stock |
C - Conversion | −4 712 969 | 0 | −100,00 | ||||
2021-09-21 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
P - Purchase | 440 000 | 11 222 662 | 4,08 | 25,00 | 11 000 000 | 280 566 550 | |
2021-09-21 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
C - Conversion | 10 084 910 | 10 782 662 | 1 445,34 | ||||
2021-09-14 | 3 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
697 752 | ||||||||
2020-12-29 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
J - Other | −103 185 | 0 | −100,00 | ||||
2020-12-29 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
J - Other | −63 481 | 0 | −100,00 | ||||
2020-07-21 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
P - Purchase | 1 200 000 | 1 707 208 | 236,59 | 1,25 | 1 500 000 | 2 134 010 | |
2020-07-21 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
P - Purchase | 400 000 | 415 244 | 2 623,98 | 1,25 | 500 000 | 519 055 | |
2020-07-21 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
P - Purchase | 180 000 | 477 120 | 60,58 | 1,25 | 225 000 | 596 400 | |
2020-01-06 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
J - Other | 38 108 | 507 208 | 8,12 | ||||
2020-01-06 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
J - Other | 15 244 | 15 244 | |||||
2020-01-06 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
J - Other | 3 811 | 297 120 | 1,30 | ||||
2019-11-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 5 464 | 5 464 | 183,00 | 999 912 | 999 912 | ||
2019-11-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 27 322 | 137 962 | 24,69 | 183,00 | 4 999 926 | 25 247 046 | |
2019-11-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 328 | 282 246 | 0,12 | 183,00 | 60 024 | 51 651 018 | |
2019-11-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 7 104 | 116 512 | 6,49 | 183,00 | 1 300 032 | 21 321 696 | |
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 317 943 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 565 658 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 336 020 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 673 024 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 741 449 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 317 943 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 565 658 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 336 020 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 673 024 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 741 449 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 317 943 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 565 658 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 336 020 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 673 024 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 741 449 | ||||||||
2018-12-12 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 418 | 281 918 | 0,51 | 59,90 | 84 931 | 16 885 535 | |
2018-12-12 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 52 809 | 109 408 | 93,30 | 60,07 | 3 172 337 | 6 572 346 | |
2018-12-12 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 29 347 | 56 599 | 107,69 | 59,53 | 1 747 036 | 3 369 355 | |
2018-12-12 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 078 | 27 252 | 4,12 | 58,62 | 63 194 | 1 597 561 | |
2018-12-12 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 26 174 | 26 174 | 57,93 | 1 516 336 | 1 516 336 | ||
2017-12-29 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 17 000 | 44 200 | 62,50 | 28,47 | 484 016 | 1 258 440 | |
2017-12-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 200 | 27 200 | 0,74 | 26,10 | 5 220 | 709 920 | |
2017-12-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 15 000 | 27 000 | 125,00 | 25,83 | 387 444 | 697 399 | |
2017-12-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 12 000 | 12 000 | 26,06 | 312 726 | 312 726 | ||
2017-12-28 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 14 866 | 34 897 | 74,21 | 24,65 | 366 489 | 860 309 | |
2017-12-28 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 49 | 20 031 | 0,25 | 23,98 | 1 175 | 480 277 | |
2017-12-28 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 19 982 | 19 982 | 24,88 | 497 228 | 497 228 | ||
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 37 492 | 431 155 | 9,52 | 24,65 | 924 283 | 10 629 178 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 6 245 | 103 185 | 6,44 | 24,65 | 153 957 | 2 543 799 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 19 672 | 748 253 | 2,70 | 24,65 | 484 970 | 18 446 532 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 14 866 | 477 457 | 3,21 | 24,65 | 366 489 | 11 770 652 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 148 | 393 663 | 0,04 | 23,98 | 3 549 | 9 438 740 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 59 982 | 393 515 | 17,98 | 24,88 | 1 492 580 | 9 792 149 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 25 | 96 940 | 0,03 | 23,98 | 599 | 2 324 301 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 9 990 | 96 915 | 11,49 | 24,88 | 248 589 | 2 411 613 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 78 | 728 581 | 0,01 | 23,98 | 1 870 | 17 468 968 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 31 471 | 728 503 | 4,52 | 24,88 | 783 118 | 18 127 923 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 49 | 462 591 | 0,01 | 23,98 | 1 175 | 11 091 406 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 19 982 | 462 542 | 4,52 | 24,88 | 497 228 | 11 509 803 | |
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
C - Conversion | −110 640 | 0 | −100,00 | ||||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
C - Conversion | −33 656 | 0 | −100,00 | ||||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
C - Conversion | −386 285 | 0 | −100,00 | ||||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
C - Conversion | −211 708 | 0 | −100,00 | ||||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
P - Purchase | 110 640 | 110 640 | 25,00 | 2 766 000 | 2 766 000 | ||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
P - Purchase | 33 656 | 33 656 | 25,00 | 841 400 | 841 400 | ||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
P - Purchase | 386 285 | 386 285 | 25,00 | 9 657 125 | 9 657 125 | ||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
P - Purchase | 211 708 | 211 708 | 25,00 | 5 292 700 | 5 292 700 | ||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
P - Purchase | 355 591 | 993 929 | 55,71 | 25,00 | 8 889 775 | 24 848 225 | |
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
P - Purchase | 102 120 | 114 946 | 796,20 | 25,00 | 2 553 000 | 2 873 650 | |
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 110 640 | 110 640 | |||||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 33 656 | 86 925 | 63,18 | ||||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 386 285 | 697 032 | 124,31 | ||||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 211 708 | 442 560 | 91,71 | ||||
2017-01-04 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 510 | 334 740 | 0,76 | 21,72 | 54 529 | 7 272 126 | |
2017-01-04 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 810 | 310 747 | 0,91 | 21,72 | 61 046 | 6 750 885 | |
2017-01-04 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 730 | 230 852 | 0,76 | 21,72 | 37 584 | 5 015 190 | |
2017-01-04 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 480 | 63 481 | 0,76 | 21,72 | 10 428 | 1 379 106 | |
2017-01-04 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 220 | 37 909 | 0,58 | 21,72 | 4 779 | 823 562 | |
2017-01-04 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 512 | 333 533 | 0,15 | 21,72 | 11 123 | 7 245 904 | |
2017-01-04 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 130 | 109 415 | 1,04 | 21,72 | 24 549 | 2 377 008 | |
2016-12-20 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 42 110 | 332 230 | 14,51 | 22,99 | 968 147 | 7 638 267 | |
2016-12-20 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 64 250 | 307 937 | 26,37 | 22,99 | 1 477 165 | 7 079 749 | |
2016-12-20 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 29 040 | 229 122 | 14,51 | 22,99 | 667 656 | 5 267 721 | |
2016-12-20 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 7 990 | 63 001 | 14,52 | 22,99 | 183 697 | 1 448 450 | |
2016-12-20 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 330 | 37 689 | 3,66 | 22,99 | 30 578 | 866 504 | |
2016-12-20 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 20 033 | 280 500 | 7,69 | 22,99 | 460 577 | 6 448 947 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 579 | 290 120 | 0,20 | 22,05 | 12 767 | 6 397 088 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 290 | 243 687 | 0,53 | 22,05 | 28 444 | 5 373 250 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 400 | 200 082 | 0,20 | 22,05 | 8 820 | 4 411 768 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 110 | 55 011 | 0,20 | 22,05 | 2 425 | 1 212 982 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 321 | 260 467 | 0,12 | 22,05 | 7 078 | 5 743 245 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 439 | 289 541 | 0,50 | 21,37 | 30 744 | 6 186 072 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 810 | 242 397 | 1,17 | 21,37 | 60 036 | 5 178 836 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 000 | 199 682 | 0,50 | 21,37 | 21 365 | 4 266 226 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 270 | 54 901 | 0,49 | 21,37 | 5 769 | 1 172 965 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 670 | 260 146 | 0,26 | 21,37 | 14 315 | 5 558 045 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 34 130 | 288 102 | 13,44 | 17,32 | 591 234 | 4 990 791 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 35 490 | 239 587 | 17,39 | 17,32 | 614 793 | 4 150 366 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 23 530 | 198 682 | 13,43 | 17,32 | 407 610 | 3 441 768 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 4 120 | 108 285 | 3,96 | 17,32 | 71 371 | 1 875 821 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 6 470 | 54 631 | 13,43 | 17,32 | 112 080 | 946 373 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 822 | 36 359 | 5,28 | 17,32 | 31 563 | 629 847 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 46 510 | 253 972 | 22,42 | 17,26 | 802 884 | 4 384 217 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 48 320 | 204 097 | 31,02 | 17,26 | 834 129 | 3 523 245 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 32 080 | 175 152 | 22,42 | 17,26 | 553 784 | 3 023 579 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 5 830 | 104 165 | 5,93 | 17,26 | 100 641 | 1 798 159 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 8 820 | 48 161 | 22,42 | 17,26 | 152 256 | 831 384 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 498 | 34 537 | 7,80 | 17,26 | 43 122 | 596 198 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 18 620 | 207 462 | 9,86 | 16,21 | 301 845 | 3 363 125 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 19 050 | 155 777 | 13,93 | 16,21 | 308 816 | 2 525 270 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 12 840 | 143 072 | 9,86 | 16,21 | 208 147 | 2 319 312 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 3 460 | 98 335 | 3,65 | 16,21 | 56 089 | 1 594 089 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 3 530 | 39 341 | 9,86 | 16,21 | 57 224 | 637 749 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 100 | 32 039 | 3,56 | 16,21 | 17 832 | 519 378 | |
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 99 922 | 99 922 | 11,00 | 1 099 142 | 1 099 142 | ||
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 72 357 | 72 357 | 11,00 | 795 927 | 795 927 | ||
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 68 912 | 68 912 | 11,00 | 758 032 | 758 032 | ||
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 18 951 | 18 951 | 11,00 | 208 461 | 208 461 | ||
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 16 366 | 16 366 | 11,00 | 180 026 | 180 026 | ||
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 53 119 | 53 119 | 11,00 | 584 309 | 584 309 | ||
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 275 047 | 332 396 | 479,60 | 11,00 | 3 025 517 | 3 656 356 | |
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 64 712 | 78 205 | 479,60 | 11,00 | 711 832 | 860 255 | |
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 132 614 | 160 265 | 479,60 | 11,00 | 1 458 754 | 1 762 915 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 34 010 | 88 920 | 61,94 | 19,75 | 671 735 | 1 756 268 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 24 630 | 64 370 | 61,98 | 19,75 | 486 470 | 1 271 378 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 23 460 | 61 320 | 61,97 | 19,75 | 463 361 | 1 211 137 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 5 880 | 30 163 | 24,21 | 19,75 | 116 136 | 595 752 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 6 450 | 16 860 | 61,96 | 19,75 | 127 395 | 333 004 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 5 570 | 14 573 | 61,87 | 19,75 | 110 014 | 287 833 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 21 690 | 54 910 | 65,29 | 19,83 | 430 074 | 1 088 766 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 15 700 | 39 740 | 65,31 | 19,83 | 311 303 | 787 973 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 14 960 | 37 860 | 65,33 | 19,83 | 296 630 | 750 696 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 3 690 | 24 283 | 17,92 | 19,83 | 73 166 | 481 488 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 4 110 | 10 410 | 65,24 | 19,83 | 81 494 | 206 412 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 3 550 | 9 003 | 65,10 | 19,83 | 70 390 | 178 513 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 310 | 33 220 | 0,94 | 19,74 | 6 119 | 655 670 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 220 | 24 040 | 0,92 | 19,74 | 4 342 | 474 482 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 210 | 22 900 | 0,93 | 19,74 | 4 145 | 451 982 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 50 | 20 593 | 0,24 | 19,74 | 987 | 406 448 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 50 | 20 593 | 0,24 | 19,74 | 987 | 406 448 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 60 | 6 300 | 0,96 | 19,74 | 1 184 | 124 344 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 6 770 | 259 476 | 2,68 | 19,17 | 129 814 | 4 975 426 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 5 130 | 32 190 | 18,96 | 19,17 | 98 367 | 617 240 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 3 720 | 23 820 | 18,51 | 19,17 | 71 331 | 456 746 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 3 540 | 22 690 | 18,49 | 19,17 | 67 879 | 435 078 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 990 | 20 543 | 5,06 | 19,17 | 18 983 | 393 910 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 970 | 6 240 | 18,41 | 19,17 | 18 600 | 119 651 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 848 | 5 403 | 18,62 | 19,17 | 16 260 | 103 602 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 14 386 | 27 780 | 107,41 | 19,49 | 280 390 | 541 446 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 10 418 | 20 100 | 107,60 | 19,49 | 203 052 | 391 759 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 9 921 | 19 150 | 107,50 | 19,49 | 193 365 | 373 243 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 712 | 19 553 | 16,10 | 19,49 | 52 858 | 381 098 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 728 | 5 270 | 107,32 | 19,49 | 53 170 | 102 715 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 360 | 4 555 | 107,52 | 19,49 | 45 998 | 88 779 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 3 014 | 13 394 | 29,04 | 18,35 | 55 307 | 245 781 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 182 | 9 682 | 29,09 | 18,35 | 40 040 | 177 666 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 079 | 9 229 | 29,08 | 18,35 | 38 150 | 169 353 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 568 | 16 841 | 3,49 | 18,35 | 10 423 | 309 034 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 572 | 2 542 | 29,04 | 18,35 | 10 496 | 46 646 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 495 | 2 195 | 29,12 | 18,35 | 9 083 | 40 278 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 400 | 10 380 | 15,59 | 17,62 | 24 669 | 182 905 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 010 | 7 500 | 15,56 | 17,62 | 17 797 | 132 157 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 970 | 7 150 | 15,70 | 17,62 | 17 092 | 125 989 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 340 | 16 273 | 2,13 | 17,62 | 5 991 | 286 745 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 270 | 1 970 | 15,88 | 17,62 | 4 758 | 34 713 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 230 | 1 700 | 15,65 | 17,62 | 4 053 | 29 956 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 6 650 | 8 980 | 285,41 | 17,56 | 116 771 | 157 685 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 4 810 | 6 490 | 286,31 | 17,56 | 84 462 | 113 962 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 4 580 | 6 180 | 286,25 | 17,56 | 80 423 | 108 518 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 610 | 15 933 | 11,24 | 17,56 | 28 271 | 279 777 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 260 | 1 700 | 286,36 | 17,56 | 22 125 | 29 851 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 090 | 1 470 | 286,84 | 17,56 | 19 140 | 25 813 | |
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 625 | 57 974 | 1,09 | 13,42 | 8 387 | 778 005 | |
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 830 | 14 323 | 6,15 | 13,42 | 11 139 | 192 213 | |
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 330 | 2 330 | 13,42 | 31 268 | 31 268 | ||
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 680 | 1 680 | 13,42 | 22 545 | 22 545 | ||
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 600 | 1 600 | 13,42 | 21 472 | 21 472 | ||
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 440 | 440 | 13,42 | 5 905 | 5 905 | ||
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 380 | 380 | 13,42 | 5 100 | 5 100 | ||
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 150 | 150 | 13,42 | 2 013 | 2 013 | ||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B common stock |
C - Conversion | −134 | 1 490 | −8,25 | ||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B common stock |
C - Conversion | −57 349 | 638 338 | −8,24 | ||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B common stock |
C - Conversion | −13 493 | 150 186 | −8,24 | ||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B common stock |
C - Conversion | −11 076 | 123 279 | −8,24 | ||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B common stock |
C - Conversion | −1 153 | 12 826 | −8,25 | ||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B common stock |
C - Conversion | −27 651 | 307 776 | −8,24 | ||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B common stock |
C - Conversion | −113 | 1 251 | −8,28 | ||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 23 890 | 252 706 | 10,44 | 14,11 | 336 997 | 3 564 721 | |
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 6 203 | 228 816 | 2,79 | 14,22 | 88 218 | 3 254 198 | |
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 28 797 | 222 613 | 14,86 | 13,26 | 381 989 | 2 952 939 | |
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 8 233 | 193 816 | 4,44 | 13,22 | 108 815 | 2 561 647 | |
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 127 691 | 185 583 | 220,57 | 12,76 | 1 629 899 | 2 368 856 | |
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 56 739 | 57 892 | 4 920,99 | 11,43 | 648 305 | 661 480 | |
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 134 | 134 | |||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 57 349 | 57 349 | |||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 13 493 | 13 493 | |||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 11 076 | 11 076 | |||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 1 153 | 1 153 | |||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 27 651 | 27 651 | |||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 113 | 113 |